搜索结果
ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
---|
化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
---|
TCMBANKIN035814 | (7E)-9-hydroxymegastigma-4, 7-dien-3-on-9-O-beta-D-glucopyranoside_qt | 208.33 | |||
TCMBANKIN036825 | Honokiol | VZ32385; 354H746; NCGC00163567-01; HMS2051C12; 11513CCO0N; {1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-; 2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; ZINC00001536; STK801954; AIDS002243; FVYXIJYOAGAUQK-UHFFFAOYSA-N; AC-486; SMP2_000040; 5,3′ C10630; AX8008971; NSC-293100; AS-15333; W-2613; 3',5-diallyl-2,4'-biphenyldiol; AC1Q7A9U; MLS000759481; TR-014635; 564-73-8; SR-01000758208-5; 3',5-Dipropenyl-(1,1'-biphenyl)-2,4'-diol; J10347; NC00114; SAM001246690; Bio-0326; MLS001423980; CHEBI:5759; 3'',5-diallylbiphenyl-2,4''-diol; REGID_for_CID_72303; O900; MolPort-002-507-432; SCHEMBL133034; InChI=1/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H; BC205226; AN-15767; ANW-56605; MCULE-5001549020; ACN-035410; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; Honokiol, >=98% (HPLC), powder; D04DQJ; CTK5J3931; BG01559998; SR-01000758208; BRD-K98493452-001-01-6; AC1L2HTG; AB0016711; AKOS005622639; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; AT-5464; 5,3''''-Diallyl-biphenyl-2,4''''-diol; RTR-014635; cid_72303; 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; CHEMBL16901; 3',5-Diallyl-2,4'-dihydroxybiphenyl; 35354-74-6; 5,3′-Diallyl-2,4′-dihydroxybiphenyl; houpa; UNII-11513CCO0N; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; CPD000387107; HY-N0003; HMS3393C12; Honokiol; Q-100425; FT-0601638; 5,3''-Diallyl-biphenyl-2,4''-diol; 3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol; BBL027819; MFCD00016674; CCG-100864; ST24044036; AK-25837; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl-; Honokiol, analytical standard; AJ-08043; BDBM50157304; 3',1'-biphenyl)-2,4'-diol; 5,3'-Diallyl-biphenyl-2,4'-diol; NSC293100; NCGC00163567-03; BG00615873; 4CN-0876; NSC 293100; H4914_SIGMA; KS-00000NQF; 3',5'-Diallyl-2,4'-biphenyldiol; SC-17371; BN0719; NCGC00163567-02; LS-174528; BB_NC-1461; s2310; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; API0002927; CS-1696; I06-0428; N1672; HMS2271J07; DTXSID30188845; SMR000387107; MLS001048916; AIDS-002243; HMS3656G03; Honokiol, HO; Honokiol, European Pharmacopoeia (EP) Reference Standard; ZINC1536; Honokiol,(S); MLS006011755; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; 5,3′-Diallyl-2,4′-dihydroxydiphenyl; 4-allyl-2-(3-allyl-4-hydroxyphenyl)phenol; 3',5-Diallylbiphenyl-2,4'-diol | 266.334 | ||
TCMBANKIN055948 | Eupachlorin acetate | enoxaparin;nadroparin | C22H27ClO8 | 420.453 | [C@]12([H])[C@](O[H])(C(C([H])([H])[H])=C([H])[C@@]1([H])OC(=O)C([H])([H])[H])[C@]3([H])[C@]([H])(C(=C([H])[H])C(=O)O3)[C@]([H])(OC(=O)\C(\C([H])([H])[H])=C([H])/C([H])([H])[H])C([H])([H])[C@]2(O[H])C ([H])([H])Cl |
TCMBANKIN058322 | baicalein | 5,6,7-trihydroxyflavanone; KBio3_002435; NCGC00025282-03; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; AIDS-000731; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; baicalein ; Sho-saiko-to; 5,6,7-trihydroxy-2-phenylchromen-4-one; ST057152; Spectrum_000427; SPECTRUM1504002; 5,6,7-trihydroxy-2-phenyl-chromone; KBio1_001798; KBio2_006043; NSC 661431; 11712_FLUKA; SDCCGMLS-0066744.P001; KBioSS_000907; CHEBI:2979; SMP1_000037; 5,6,7-trihydroxy-2-phenyl-4-chromenone; LMPK12140610; SPBio_000572; NCGC00025282-02; Dihydrobaicalein; Baicalein; 5,6,7-trihydroxy-2-phenyl-chroman-4-one; Spectrum4_000537; KBioGR_001173; 491-67-8; NCGC00017236-01; S00113; 465119_ALDRICH; Spectrum5_001418; Oprea1_765614; Tocris-1761; DivK1c_006854; NSC729192; AIDS000731; BSPBio_003215; SCHEMBL12068882; 5,6,7-Trihydroxyflavone; Spectrum3_001608; KBio2_003475; SpecPlus_000758; 5,6,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one; NSC661431; NCGC00025282-01; 5,6,7-trihydroxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one; C10023; Spectrum2_000466; TNP00121; KBio2_000907; ZINC00017881; Biacalein; 5,6,7-trihy-droxyflavone | C15H10O5 | 270.24 g/mol | C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O |
TCMBANKIN058964 | heparin | enoxaparin;nadroparin | C26H42N2O37S5 | 1134.9 g/mol | CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O |
TCMBANKIN059452 | ethyl aldehyde | C2H4O | 44.05 g/mol | CC=O |
疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
---|
TCMBANKDI000002 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Sign or Symptom | phenotype | |
TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
TCMBANKDI001895 | Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Eye Diseases; Nervous System Diseases; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
TCMBANKDI005370 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Constitutional symptom; Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI008601 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI009152 | - | - | Congenital Abnormality | disease | |
TCMBANKDI011079 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
TCMBANKDI013541 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
TCMBANKDI014088 | Respiratory Tract Diseases; Cardiovascular Diseases | Abnormality of the respiratory system; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI020257 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI020278 | Eye Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI023834 | Nervous System Diseases | - | Disease or Syndrome | group | |
TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI026963 | Pathological Conditions, Signs and Symptoms | - | Acquired Abnormality | disease | |
TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI031192 | Neoplasms; Male Urogenital Diseases | - | Neoplastic Process | disease |